etoposide has been researched along with Ataxia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maggs, FG | 1 |
| Becherel, OJ; Chen, P; de Murcia, G; de Murcia, JM; Epe, B; Fusser, M; Grattan-Smith, P; Gueven, N; Haince, JF; Howe, O; Lavin, MF; McGowan, CH; Mothersill, C; Ouellet, ME; Parton, R; Poirier, GG; Waterhouse, N | 1 |
| Berthaud, P; Dick, G; Pein, F; Pinkerton, R; Pritchard-Jones, K; Vassal, G | 1 |
| Anderson, D; Leonetti, JP; Marzo, S; Shirazi, MA | 1 |
4 other study(ies) available for etoposide and Ataxia
| Article | Year |
|---|---|
The patient with ataxia.
Topics: Acute Disease; Aged; Antineoplastic Agents; Ataxia; Carboplatin; Diagnosis, Differential; Etoposide; Humans; Lung; Lung Neoplasms; Male; Palliative Care; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2014 |
A novel form of ataxia oculomotor apraxia characterized by oxidative stress and apoptosis resistance.
Topics: Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Apraxias; Ataxia; Blotting, Western; Camptothecin; Cells, Cultured; DNA Breaks, Single-Stranded; DNA Damage; DNA Repair; Etoposide; Female; Flow Cytometry; Humans; Hydrogen Peroxide; Male; Membrane Potential, Mitochondrial; Methylnitronitrosoguanidine; Mitomycin; Oxidative Stress; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Radiation, Ionizing; Reactive Nitrogen Species | 2007 |
Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Ataxia; Child; Child, Preschool; Cohort Studies; Cyclosporins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Feasibility Studies; Female; Gastrointestinal Diseases; Humans; Infant; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local | 2007 |
Neuroendocrine carcinoma of the jugular foramen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Diagnosis, Differential; Etoposide; Female; Headache; Hearing Loss, Sensorineural; Humans; Jugular Veins; Magnetic Resonance Imaging; Middle Aged; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Skull Base Neoplasms; Tinnitus; Vertigo | 2008 |